About Cell MedX (OTCMKTS:CMXC)
Cell MedX Corp. is a development-stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases, such as diabetes, by developing technologies to help manage the illness and related complications. The Company, through its subsidiary, Avyonce Cosmedics Inc. (Avyonce), is engaged in reselling and marketing spa technology and equipment to the beauty and wellness industry. Avyonce is involved in carrying out observational studies using eBalance Technology. The eBalance Technology is used for the use of micro currents for the treatment of diabetes and related ailments. Avyonce also provides continuing education to the estheticians and healthcare professionals in the field of medical aesthetics. The Company is engaged in developing a family of devices based on the eBalance Technology.
Industry, Sector and Symbol
Trailing P/E Ratio-8.075
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on Assets-160.14%
Cell MedX (OTCMKTS:CMXC) Frequently Asked Questions
What is Cell MedX's stock symbol?
Cell MedX trades on the OTCMKTS under the ticker symbol "CMXC."
Who are some of Cell MedX's key competitors?
Some companies that are related to Cell MedX include Premier (PRHL), Black Ridge Oil & Gas (ANFC), Pacific Drilling (PACDQ), Destiny Media Technologies (DSNY), OMNI-LITE INDS CAN (OLNCF), Atna Resources (ATNAQ), Windtree Therapeutics (WINT), Deep Down (DPDW), Fenix Parts (FENX), B456 Systems (AONEQ), Critical Outcome T (COTQF), P10 (PIOIQ), Connecture (CNXR), Acorn Energy (ACFN), LDK Solar (LDKYQ), Cool Technologies (WARM), Talon International (TALN) and Suntech Power (STPFQ).
Who are Cell MedX's key executives?
Cell MedX's management team includes the folowing people:
- Frank Edward McEnulty, President, Director (Age 59)
- Terrance G. Owen Ph.D., Chief Executive Officer (Age 69)
- Yanika S. Silina, Chief Financial Officer, Treasurer, Secretary, Director (Age 37)
- Bradley S. Hargreaves, Vice President - Technology and Operations, Director (Age 56)
- John Sanderson M.D., Chief Medical Officer (Age 65)
How do I buy Cell MedX stock?
Shares of Cell MedX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cell MedX's stock price today?
One share of Cell MedX stock can currently be purchased for approximately $0.16.
How big of a company is Cell MedX?
Cell MedX has a market capitalization of $7.11 million.
How can I contact Cell MedX?
Cell MedX's mailing address is 123 W Nye Ln Ste 446, CARSON CITY, NV 89706-0899, United States. The company can be reached via phone at +1-310-5089398.
MarketBeat Community Rating for Cell MedX (CMXC)MarketBeat's community ratings are surveys of what our community members think about Cell MedX and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cell MedX (OTCMKTS:CMXC) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Cell MedX (OTCMKTS:CMXC)
No earnings announcements for this company have been tracked by MarketBeat.com
Cell MedX (OTCMKTS:CMXC) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Cell MedX (OTCMKTS:CMXC)
No dividend announcements for this company have been tracked by MarketBeat.com
Cell MedX (OTCMKTS CMXC) Insider Trading and Institutional Ownership History
Cell MedX (OTCMKTS CMXC) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/12/2017||Frank Mcenulty||CEO||Buy||481,016||$0.25||$120,254.00|| |
|8/21/2017||Richard Jeffs||Major Shareholder||Buy||1,000||$0.29||$290.00||2,516,126|| |
|6/15/2017||Richard Jeffs||Major Shareholder||Buy||2,690||$0.27||$726.30||2,514,956|| |
|6/9/2017||Richard Jeffs||Major Shareholder||Buy||50,000||$0.18||$9,000.00||2,512,266|| |
|5/11/2017||Richard Jeffs||Major Shareholder||Buy||5,000||$0.35||$1,750.00||2,462,266|| |
|5/5/2017||Richard Jeffs||Major Shareholder||Buy||12,800||$0.43||$5,504.00||2,455,666|| |
|4/10/2017||Richard Jeffs||Major Shareholder||Buy||5,190||$0.32||$1,660.80||2,445,666|| |
|3/23/2017||Richard Jeffs||Major Shareholder||Buy||21,560||$0.36||$7,761.60||2,428,916|| |
|3/13/2017||Richard Jeffs||Major Shareholder||Buy||9,500||$0.27||$2,565.00||2,414,416|| |
|3/8/2017||Richard Jeffs||Major Shareholder||Buy||20,000||$0.30||$6,000.00||2,394,416|| |
|3/1/2017||Richard Jeffs||Major Shareholder||Buy||10,000||$0.28||$2,800.00||2,389,416|| |
|2/28/2017||Richard Jeffs||Major Shareholder||Buy||18,984||$0.26||$4,935.84||2,370,432|| |
|1/18/2017||Richard Jeffs||Major Shareholder||Buy||10,000||$0.31||$3,100.00||2,360,432|| |
|1/10/2017||Richard Jeffs||Major Shareholder||Buy||10,000||$0.30||$3,000.00||2,350,432|| |
|1/9/2017||Richard Jeffs||Major Shareholder||Buy||58,500||$0.28||$16,380.00||2,284,432|| |
|12/30/2016||Richard Jeffs||Major Shareholder||Buy||4,500||$0.26||$1,170.00||2,280,432|| |
|12/23/2016||Richard Jeffs||Major Shareholder||Buy||7,500||$0.25||$1,875.00||2,272,432|| |
|12/14/2016||Richard Jeffs||Major Shareholder||Buy||100||$0.22||$22.00||2,269,932|| |
|12/6/2016||Richard Jeffs||Major Shareholder||Buy||5,000||$0.25||$1,250.00||2,269,832|| |
|12/5/2016||Richard Jeffs||Major Shareholder||Buy||21,100||$0.23||$4,853.00||2,253,732|| |
|11/23/2016||Richard Jeffs||Major Shareholder||Buy||13,500||$0.24||$3,240.00||2,233,732|| |
|11/15/2016||Richard Jeffs||Major Shareholder||Buy||7,500||$0.25||$1,875.00||2,223,732|| |
|11/10/2016||Richard Jeffs||Major Shareholder||Buy||17,500||$0.26||$4,550.00||2,210,232|| |
|11/2/2016||Richard Jeffs||Major Shareholder||Buy||5,000||$0.25||$1,250.00||2,205,232|| |
|10/14/2016||Richard Jeffs||Major Shareholder||Buy||8,000||$0.27||$2,160.00||2,200,232|| |
|10/4/2016||Richard Jeffs||Major Shareholder||Buy||10,000||$0.22||$2,200.00||2,192,232|| |
|9/22/2016||Richard Jeffs||Major Shareholder||Buy||5,000||$0.20||$1,000.00||2,177,262|| |
|9/14/2016||Richard Jeffs||Major Shareholder||Buy||24,332||$0.20||$4,866.40||2,167,232|| |
|8/23/2016||Richard Jeffs||Major Shareholder||Buy||10,000||$0.15||$1,500.00||2,152,900|| |
|8/17/2016||Richard Jeffs||Major Shareholder||Buy||10,250||$0.17||$1,742.50||2,142,900|| |
|8/16/2016||Richard Jeffs||Major Shareholder||Buy||9,750||$0.17||$1,657.50||2,130,650|| |
Cell MedX (OTCMKTS CMXC) News Headlines
Cell MedX (OTCMKTS:CMXC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Cell MedX (OTCMKTS CMXC) Stock Chart for Tuesday, February, 20, 2018